Dr. Willson stated, "I am excited to be working with CytoGenix to bring synDNA™ into the realm of commercial scale manufacturing. This novel drug substance represents an opportunity to develop many new products with distinct advantages over existing plasmid-based technology."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.